WOCN continued is advocacy efforts in support of the Lymphedema Treatment Act (LTA) by sending leadership in the House and Senate a letter asking that they move this important legislation. Shortly after receiving the letter the House Energy & Commerce Committee took up the LTA and passed the bill favorable out of committee, without any opposition, paving the way for the bill to be voted on by the entire House. This is an important first step in the legislative process and helps move the bill towards and eventual vote in the Senate.


As you may recall, the legislation would amend Medicare statute to pay for compression garments, bandages and supplies to reduce lymphedema-related swelling and prevent recurrence. Compression therapy is considered the gold standard for the treatment of lymphedema and the treatment and prevention of venous leg ulcers (VLUs), also known as stasis ulcers. The WOCN Society strongly supports the Lymphedema Treatment Act; this legislation reflects the vision and core tenets of the WOCN Society as a means to support cost-effective, evidence-based prevention and treatment of complex wound conditions such as VLUs and lymphedema.


WOCN also provided support for an independent cost analysis/impact study regarding the Lymphedema Treatment Act. Avalere recently completed a savings analysis showing that enactment of the Lymphedema Treatment Act (S.1315/H.R.3630) will save the Medicare program a substantial amount – $1.3 to $1.5 billion during the first 10 years, with additional savings likely. Savings will also result in the Medicaid and private insurance categories.